Back to top

Analyst Blog

Alexion Pharmaceuticals, Inc. (ALXN - Analyst Report) provided additional information on its voluntary recall of two lots of the company’s sole marketed product Soliris. Alexion stated that this voluntary move was prompted by the presence of visible particles in vials in the two lots of the drug. Alexion believes these have the potential to affect the safety of patients in two broad areas: immunogenicity and thromboembolic events.

Alexion said that it has issued instructions to hospitals as well as users to return unused vials of Soliris from both the affected lots . Last month, Alexion had given similar instructions but they were limited to the distributor level.

Soliris is available for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome (aHUS). Japanese approval for Soliris in the aHUS indication came in Sep 2013.

Alexion believes the voluntary recall will not impact the supply of Soliris. Though current supplies of Soliris may not be interrupted, we believe further slipups regarding Soliris will impact the drug’s supplies. This will be catastrophic for the company since it is entirely dependent on Soliris for growth.

We note that this is not the first setback for Alexion regarding Soliris this year. In March, the U.S. Food and Drug Administration (FDA) issued a warning letter to Alexion as the company did not comply with the current Good Manufacturing Practices (cGMP) at its manufacturing facility at Rhode Island. Alexion manufactures Soliris at the facility. An FDA re-inspection is scheduled in the first half of 2014. We believe that any slip on the company’s part to comply with the FDA’s quality control requirements will invite strict action from the agency. Such an action will affect the supplies of Soliris.

Alexion, a biopharmaceutical company, carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biopharma space include Actelion Ltd. (ALIOF), Jazz Pharmaceuticals (JAZZ - Analyst Report) and Vanda Pharmaceuticals Inc. . All these stocks carry a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
STRATTEC SE… STRT 80.24 +3.00%
PATTERSON-U… PTEN 34.54 +2.98%